Kerin Adelson, MD
Associate Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Medical Oncology
Primary
Contact Info
Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, CT 06520-8028
United States
About
Titles
Associate Professor Adjunct
Biography
Dr. Adelson is an Adjunct Associate Professor and was previously Chief Quality Officer for Yale Cancer Center and Smilow Cancer Hospital. Dr. Adelson graduated from Yale University School of Medicine, completed residency at Mount Sinai Medical Center and Fellowship in oncology at Columbia Presbyterian. In her Quality role, Dr. Adelson focused on improving care coordination for all patients treated in the Smilow network, aligning care with national quality metrics, and developing models to enhance patient involvement in decisions about their cancer-care. Dr. Adelson sits on several national committees including the Southwest Oncology group Cancer Delivery Committee, the National Cancer Care Network Policy Committee and the American Society of Clinical Oncology Health Information Technology Committee.
Appointments
Medical Oncology
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Internal Medicine
- Medical Oncology
- Pusztai Lab
- Subset Medical Oncology Faculty
- Yale Cancer Center
Education & Training
- Fellowship
- Columbia University College of Physicians and Surgeons (2007)
- Residency
- Mount Sinai School of Medicine (2003)
- Internship
- Mount Sinai School of Medicine (2001)
- MD
- Yale School of Medicine (2000)
Research
Overview
Dr. Adelson is actively involved in breast cancer clinical research and serves as an investigator on multiple clinical trials.
Medical Subject Headings (MeSH)
Breast
Research at a Glance
Yale Co-Authors
Frequent collaborators of Kerin Adelson's published research.
Publications Timeline
A big-picture view of Kerin Adelson's research output by year.
Cary Gross, MD
Lajos Pusztai, MD, DPhil
Maureen Canavan, PhD, MPH
Anne Chiang, MD, PhD
Andrea Silber, MD
Roy S. Herbst, MD, PhD
125Publications
1,863Citations
Publications
2024
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioPrognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma
Shimer S, Allen O, Yang C, Canavan M, Westvold S, Kim N, Morillo J, Parker T, Wallace N, Smith C, Adelson K. Prognostic Understanding, Goals of Care, and Quality of Life in Hospitalized Patients with Leukemia or Multiple Myeloma. Journal Of Palliative Medicine 2024, 27: 879-887. PMID: 38990245, DOI: 10.1089/jpm.2023.0530.Peer-Reviewed Original ResearchAltmetricConceptsGoals of carePrognostic awarenessQuality of lifeIllness understandingPrognostic understandingMultiple myelomaHematologic malignanciesAcute leukemiaFaith-based responseInformed treatment choicesChi-square testCohort of patientsLikelihood ratio chi-square testMount Sinai HospitalTreatment goalsMM cohortSinai HospitalCarePatient populationTreatment choiceHospitalized patientsHematologistsAssess discordanceLeukemiaPatientsSystemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
Adelson K, Cheng L, Huang Y, Niu J, Zhao H, Nortje N, Xiang J, Giordano S, Canavan M. Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis. Journal Of Clinical Oncology 2024, 42: 11092-11092. DOI: 10.1200/jco.2024.42.16_suppl.11092.Peer-Reviewed Original ResearchConceptsSystemic anticancer therapyCombined chemo-immunotherapyLiquid tumorsSolid tumorsDay of deathEmergency departmentRates of systemic therapySystemic anti-cancer therapySEER-Medicare databaseAnti-cancer therapyChemo-immunotherapyLT patientsSystemic therapyCI patientsSEER-MedicareST patientsIdentified patientsCost of drugsAssociated with higher costsEnd of lifeAnticancer therapyImmunotherapyChemotherapyPatientsTherapyCommunity Health Worker Navigation for Patients With Cancer: It Is Time to Scale up
Adelson K, Rocque G. Community Health Worker Navigation for Patients With Cancer: It Is Time to Scale up. Journal Of Clinical Oncology 2024, 42: 491-493. PMID: 38175984, DOI: 10.1200/jco.23.01723.Peer-Reviewed Original ResearchAltmetric
2022
Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era
Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsSelf-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott W, Chen K, Peters G, Reddy K, Weintraub S, Mougalian S, Adelson K, Evans S. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e340. PMCID: PMC9595452, DOI: 10.1016/j.ijrobp.2022.07.1432.Peer-Reviewed Original ResearchOncology-hospitalist co-management: A model for efficient, high-quality care and education.
Morris J, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Rothberg BE, Adelson K. Oncology-hospitalist co-management: A model for efficient, high-quality care and education. Journal Of Clinical Oncology 2022, 40: 1-1. DOI: 10.1200/jco.2022.40.28_suppl.001.Peer-Reviewed Original ResearchCitationsConceptsEarly discharge ratesReadmission ratesOncologist satisfactionIntervention teamHospitalist comanagementInpatient oncology serviceSmilow Cancer HospitalOutcome metricsHigher readmission ratesLength of stayMultidisciplinary steering groupHigh-quality careInternal medicine hospitalistsIllness scoresOncology teamCancer HospitalComparator groupOncology servicesPatient populationOutcome comparisonsCase volumeImprovement interventionsPDSA cyclesOncologistsPDSA 2Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm DL, Pusztai L. Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC. Clinical Cancer Research 2022, 28: 3720-3728. PMID: 35903931, PMCID: PMC9444984, DOI: 10.1158/1078-0432.ccr-22-0862.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImmune-related adverse eventsTriple-negative breast cancerNon-AA patientsEvent-free survivalPhase I/II clinical trialsClinical trialsNeoadjuvant chemotherapyOverall survivalAA patientsEarly-stage triple-negative breast cancerIncidence of irAEsPathologic complete response rateSignificant associationMultivariate logistic regression analysisTumor-infiltrating lymphocyte countsComplete response ratePrimary efficacy endpointPD-L1 statusProportional hazards modelLogistic regression analysisAfrican American womenEFS ratesNeoadjuvant immunotherapyEfficacy endpointAdverse eventsClinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
Foldi J, Kahn A, Silber A, Qing T, Reisenbichler E, Fischbach N, Persico J, Adelson K, Katoch A, Chagpar A, Park T, Blanchard A, Blenman K, Rimm D, Pusztai L. Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC. Journal Of Clinical Oncology 2022, 40: 516-516. DOI: 10.1200/jco.2022.40.16_suppl.516.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsTriple-negative breast cancerMultivariate logistic regression analysisPD-L1 statusLogistic regression analysisAA raceOverall survivalPathologic responseClinical trialsBreast cancerEarly-stage triple-negative breast cancerIncidence of irAEsPhase I/II trialPathologic complete response rateSignificant associationPhase I/II clinical trialsBaseline body mass indexSafety of immunotherapyWeekly nab-paclitaxelCharlson Comorbidity IndexComplete response ratePrimary efficacy endpointPD-L1 expressionBody mass indexBreast cancer recurrenceSelf-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings
Talcott WJ, Chen K, Peters GW, Reddy KK, Weintraub SM, Mougalian SS, Adelson K, Evans SB. Self-Reported COVID-19 Infections and Social Mixing Behavior at Oncology Meetings. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: 30-38. PMID: 35598798, PMCID: PMC9119957, DOI: 10.1016/j.ijrobp.2022.05.002.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSelf-reported COVID-19 infectionCOVID-19 infectionOncology meetingsEra of vaccinationCOVID-19 positivityCOVID-19 positivity ratesOncology annual meetingsPerson attendeesAmerican SocietyCOVID-19Risk of diseasePerson meetingsPositivity rateNew COVID-19 infectionsResponse rateEvent ratesSocial distancing mandates
News & Links
News
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
- March 11, 2024
Oncology Hospitalists Improve Hospice Transitions for Patients with Advanced Cancers
- July 03, 2023Source: AJMC
Poster Talks Explore How Policy, Payer Incentives Affect Cancer Care, Outcomes
- March 08, 2023
Involving Hospitalists in Inpatient Cancer Care Reduces Patient Stays, Oncologist Stress
Get In Touch
Contacts
Mailing Address
Yale Cancer Center
333 Cedar Street, PO Box 208028
New Haven, CT 06520-8028
United States